Doxycycline controlled-release - CollaGenex Pharmaceuticals

Drug Profile

Doxycycline controlled-release - CollaGenex Pharmaceuticals

Alternative Names: Apprilon; COL 101; Col-101; Efracea; Oracea; Oraycea

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator CollaGenex Pharmaceuticals
  • Developer Galderma
  • Class Antibacterials; Antimalarials; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rosacea

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Feb 2013 Launched for Rosacea in Canada (PO)
  • 19 Nov 2010 Efficacy data from ORCA (Oracea® for Rosacea: A Community-Based Assessment) trial released by Galderma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top